Other predictive markers include mutations in KRAS/NRAS and BRAF V600E, tumor mutational burden, and imaging-based radiomic parameters such as metabolic tumor volume (MTV) and total lesion glycolysis on PET/CT. Here, KRAS is linked to neoplasm.